Lakshyaditya Aithani

Raymond James & Associates, Inc. (RJA) is a registered broker-dealer headquartered in St. Petersburg, Florida. The firm was founded in 1962 and is a subsidiary of Raymond James Financial, Inc. (NYSE: RJF), a diversified holding company. RJA offers a full array of capital markets services, strategic advice and planning for institutional investors.

JSB-Partners LP offers specialized investment banking and advisory services to biotechnology and pharmaceutical companies. Its services include product partnerships, mergers and acquisitions, private placements and public underwritings. The company was founded by Wolfgang Rudolph Ralph Stoiber in 1999 and is headquartered in Boston, MA.

Symbiomix Therapeutics LLC develops medicines for women’s health infections and related diseases. It offers SYM-1219, a drug that contains secnidazole that facilitate administration as a single-dose oral therapy for various women's health infections including bacterial vaginosis. The company was founded by Jack Roberts, Steve Pomerantz and Joseph L. Amprey III in 2012 and is headquartered in Newark, NJ.

Click Therapeutics, Inc. develops and commercializes software as prescription medical treatments for people with unmet medical needs. The company is headquartered in New York, NY.

GPC Biotech, Inc. discovers and develops anticancer drugs through discovery technologies and development approaches. It is a mechanism-based drug discovery and development company focused on treatments for cancer and fungal infections. The company is a wholly owned subsidiary of GPC Biotech AG. GPC Biotech was founded in 1992 and is located in Waltham, MA.

Wachtell, Lipton, Rosen & Katz provides advisory and legal services. It specializes in mergers and acquisitions, strategic investments, takeovers and takeover defense, corporate and securities law, and corporate governance. The company was founded in 1965 and is headquartered in New York, NY.

Flagship Pioneering (Flagship Pioneering) is a venture capital firm founded in 1982 by Ed M Kania and Noubar B Afeyan. The firm is headquartered in Cambridge, Massachusetts.

Gilead Connecticut, Inc. manufactures pharmaceuticals and biotechnology chemicals. The firm develops a pipeline of small molecule therapeutics for multiple oncology and immunology-based indications. It focuses on the development of novel kinase inhibitors for the treatment of cancer, autoimmune, and inflammatory diseases. The company was founded in 2000 and is headquartered in Foster City, CA.

OrbiMed Advisors Private Equity (OrbiMed Advisors Private Equity) is a private equity and venture capital subsidiary of Orbimed Advisors LLC founded in 1993 by Samuel D. Isaly. The firm is headquartered in New York and it has additional offices in San Francisco, Mumbai, Shanghai, Herzliya, Hong Kong and London.

Part of Shell Plc, Shell Research Ltd. is a British company that provides business support services. The company is based in London, UK.

Avitide, Inc. develops affinity purification solutions. Its technology enables development of chromatography resins via chemical synthesis which are not based on costly recombinant proteins. The company was founded by Errik B. Anderson, Warren Kett, Tillman U. Gerngross, Kevin Isett and Jonathan Sheller in 2012 and is headquartered in Lebanon, NH.

Impresa Management LLC(Impresa Management) is a Private Equity/Venture Capital firm, a subsidiary of Devonshire Investors LLC founded in 1946.The firm is headquartered in Boston.

Orbimed Private Investments VI LP seeks investment opportunities companies located in North America and Europe. The fund targets companies operating in the fields of biopharmaceutical, medical device, diagnostics and healthcare services. It provides financing for seed stage, early stage, and later stage companies for both public and private companies with an investment size of $10 million to $75 million.

Turnstone Biologics, Inc. develops bio-therapeutics for the treatment of cancer. It develops Maraba oncolytic viral immunotherapy, a platform representing a disruptive approach in the treatment of cancer. The company was founded by David Stojdl, Brian D. Lichty and John C. Bell and is headquartered in Ottawa, Canada.

Attenua, Inc. engages in the provision of biopharmaceutical services. The company was founded by Jing Liang and is headquartered in San Mateo, CA.

Pionyr Immunotherapeutics, Inc. develops cancer immunotherapies. It targets the tumor microenvironment to enhance the body?s antitumor immunity. The company was founded by Max Krummel and Sachdev Sidhu in 2015 and is headquartered in San Francisco, CA.

Meves Pharmaceuticals, Inc. provides pharmaceutical products and services. The company is headquartered in New York, NY.

Modis Therapeutics, Inc. is a biopharmaceutical company, which develops disease-modifying therapies for rare genetic diseases. Its product MT1621 is in clinical development for thymidine kinase 2 deficiency (TK2d), an inherited mitochondrial disease. The company was founded by Peter H. Barber and Daniel D. DiPietro in 2016 and is headquartered in Oakland, CA.

EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA.

Charm Therapeutics Ltd. is a British London-based company that is discovering and developing small molecule medicines using its proprietary 3D deep learning-enabled platform, Dragonfold. The company aims to create life-changing therapies for difficult-to-drug targets in cancer and other disease areas. Charm Therapeutics has raised $70 million to date and is supported by high-quality international investors, including Orbimed, F-Prime Capital, General Catalyst, Khosla Ventures, Bristol Myers Squibb, NVIDIA, and Grep-VC. The company was founded in 2021 by Laksh Aithani and David Baker, with Laksh Aithani serving as the CEO since then.

Aer Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Raleigh, NC. The company's mission is to advance the treatment paradigm for mucus mediated lung diseases. The company is dedicated to delivering a therapeutic solution to patients suffering from muco-obstructive lung diseases, with their initial focus being on chronic obstructive pulmonary disease (COPD) and other muco-obstructive lung diseases to follow, including asthma, cystic fibrosis, and primary ciliary. The company was founded by John Fahy, and the CEO is Jim Shaffer.

AviadoBio Ltd. is a gene therapy company based in London, UK. AviadoBio's technology is based on pioneering research from King's College London and the UK Dementia Research Institute. The British company's mission is to develop and deliver transformative gene therapies for neurodegenerative disorders, including frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS). The company is developing AVB-101 for patients with FTD-GRN. AviadoBio's investors include New Enterprise Associates (NEA), Monograph Capital, Advent Life Sciences, EQT Lifesciences, Dementia Discovery Fund (DDF), F-Prime Capital, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and LifeArc. The company was founded by Youn Bok Lee, Do Young Lee, Chris E. Shaw, and Lisa Deschamps has been the CEO of the company since 2021.